Technical Analysis for EPZM - Epizyme, Inc.

Grade Last Price % Change Price Change
grade D 9.56 0.00% 0.00
EPZM closed unchanged on Friday, January 18, 2019, on 65 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Flat
See historical EPZM trend table...

Date Alert Name Type % Chg
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 180 Bullish Setup Bullish Swing Setup 0.00%
Jan 17 Narrow Range Bar Range Contraction 0.00%
Jan 17 NR7 Range Contraction 0.00%
Jan 17 Wide Bands Range Expansion 0.00%
Jan 17 Overbought Stochastic Strength 0.00%
Jan 17 Down 3 Days in a Row Weakness 0.00%
Jan 17 Down 4 Days in a Row Weakness 0.00%
Jan 16 Multiple of Ten Bearish Other -0.83%

Older signals for EPZM ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Epizyme, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, planning, and commercialization of various personalized therapeutics for the treatment of patients with genetically defined cancers. Its principal product candidates under development include EPZ-5676, an intravenously administered small molecule inhibitor of DOT1L that is in Phase I clinical trials for the treatment of mixed lineage rearranged leukemia (MLL-r); and EPZ-6438, an orally available small molecule inhibitor of EZH2 for the treatment of non-Hodgkin lymphoma patients caused by an oncogenic point mutation in EZH2. The company has strategic collaboration and license agreements with Celgene Corporation and Celgene International Sàrl, as well as Glaxo Group Limited to discover, develop, and commercialize small molecule HMT inhibitors; and Eisai Co., Ltd. (Eisai) to license its EZH2 program. It also has a companion diagnostic collaboration with Abbott Molecular Inc. for the development of a companion diagnostic to identify patients with the MLL-r genetic alteration targeted by EPZ-5676; and with Roche Molecular Systems, Inc., as well as with Eisai for the development and commercialization of a companion diagnostic for use with EPZ-6438 product candidate. The company was founded in 2007 and is headquartered in Cambridge, Massachusetts.
Is EPZM a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 21.4
52 Week Low 5.14
Average Volume 857,092
200-Day Moving Average 11.3109
50-Day Moving Average 7.3484
20-Day Moving Average 7.8095
10-Day Moving Average 9.608
Average True Range 0.6816
ADX 45.39
+DI 31.2131
-DI 10.6018
Chandelier Exit (Long, 3 ATRs ) 8.4252
Chandelier Exit (Short, 3 ATRs ) 7.1848
Upper Bollinger Band 11.6362
Lower Bollinger Band 3.9828
Percent B (%b) 0.73
BandWidth 98.001152
MACD Line 0.8618
MACD Signal Line 0.6447
MACD Histogram 0.2171
Fundamentals Value
Market Cap 558.94 Million
Num Shares 58.5 Million
EPS -2.07
Price-to-Earnings (P/E) Ratio -4.62
Price-to-Sales 55.00
Price-to-Book 6.25
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 10.18
Resistance 3 (R3) 10.18 9.98 10.07
Resistance 2 (R2) 9.98 9.82 9.98 10.04
Resistance 1 (R1) 9.77 9.73 9.67 9.77 10.00
Pivot Point 9.57 9.57 9.52 9.57 9.57
Support 1 (S1) 9.36 9.41 9.26 9.36 9.12
Support 2 (S2) 9.16 9.32 9.16 9.08
Support 3 (S3) 8.95 9.16 9.05
Support 4 (S4) 8.95